search
Back to results

A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants

Primary Purpose

Hand, Foot and Mouth Disease

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
160Eu/0.5ml in adults
320Eu/0.5ml in adults
640Eu/0.5ml in adults
1280Eu/0.5ml (without adjuvant) in 12 adults
0Eu/0.5ml in adults
160Eu/0.5ml in children
320Eu/0.5ml in children
640Eu/0.5ml in children
1280Eu/0.5ml (without adjuvant) in children
0Eu/0.5ml in children
160Eu/0.5ml in infants
320Eu/0.5ml in infants
640Eu/0.5ml in infants
1280Eu/0.5ml (without adjuvant) in infants
0Eu/0.5ml in infants
Sponsored by
Institute of Medical Biology, Chinese Academy of Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hand, Foot and Mouth Disease focused on measuring Human Enterovirus 71 (EV71), Hand, Foot and Mouth Disease, Inactivated Vaccine, Human Diploid cell, Safety, Immunogenicity, Adverse reactions associated with vaccine

Eligibility Criteria

6 Months - 49 Years (Child, Adult)All SexesAccepts Healthy Volunteers

For the subjects aged from 18-49 years old adults:

Inclusion Criteria:

  • Healthy subjects (18-49 years old adults) as established by medical history and clinical examination
  • The subjects oneself or their legal guardian must be aware of this vaccines
  • Voluntarily participate in the study and signed Informed Consent Form
  • Subjects with temperature ≤ 37.0℃
  • With the ability and objective to comply with the requirements of the protocol
  • Persist for a 2-month visit and receive blood tests according to program requirements

Exclusion Criteria:

  • Subject who has a clinical diagnosis history of Hand, Foot and Mouth Disease (HFMD)
  • Allergy or serious side-effects to a vaccine or any ingredient of vaccine
  • Epilepsy, seizures, convulsions, neurological illness
  • Congenital or hereditary immunodeficiency
  • Autoimmune disease
  • Severe malnutrition or dysgenopathy
  • Asthma, thyroidectomy, angioneurotic edema, diabetes or cancer
  • Asplenia, functional asplenia, and any circumstances leading to the asplenia or splenectomy
  • Clinical diagnosis of coagulopathy (such as clotting factor deficiency, coagulation disorders, platelet abnormalities), significant bruising or blood clotting disorder
  • Acute illness or acute exacerbation of chronic disease in last 7 days
  • Any prior administration of immunodepressant or corticosteroids in last 6 months
  • Any prior administration of blood products in last 3 months
  • Any prior administration of live-attenuated vaccine in last 28 days or 1 months
  • Any prior administration of subunit or inactivated vaccines in last 14 days
  • Under the anti-TB prevention or therapy
  • Fever before vaccination, axillary temperature ﹥37.0℃
  • The laboratory test abnormalities before vaccination, including blood tests (hemoglobin, total white blood cells, WBC, platelets), blood biochemistry tests (ALT, total bilirubin, direct bilirubin, Cr, BUN) and urine tests (urine protein, urine sugar, blood cells), etc.
  • Hypertension or hypotension. Systolic blood pressure ﹥140mmHg and/or diastolic blood pressure ﹥90mmHg; systolic blood pressure ﹤90mmHg and/or diastolic blood pressure ﹤60mmHg
  • Breast-feeding, pregnant, planning a pregnancy within 60 days or positive pregnancy test women
  • Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

For the subjects aged from 3-11 years old children:

Inclusion Criteria:

  • Healthy subjects (3-11 years old children) as established by medical history and clinical examination
  • Full-term (37-42 weeks), weight ≥ 2500 g when it was born
  • The subjects' legal guardian must be aware of this vaccines
  • The subjects' legal guardian voluntarily participate in the study and signed Informed Consent Form
  • Subjects with temperature ≤ 37.0℃
  • The subjects' legal guardian with the ability and objective to comply with the requirements of the protocol
  • Persist for a 2-month visit and receive blood tests according to program requirements

Exclusion Criteria:

  • Subject who has a clinical diagnosis history of Hand, Foot and Mouth Disease (HFMD)
  • ≤37 weeks gestation
  • weight ≤ 2500 g when it was born
  • Allergy or serious side-effects to a vaccine or any ingredient of vaccine
  • Epilepsy, seizures, convulsions, neurological illness
  • Congenital or hereditary immunodeficiency
  • Autoimmune disease
  • Severe malnutrition or dysgenopathy
  • Asthma, thyroidectomy, angioneurotic edema, diabetes or cancer
  • Asplenia, functional asplenia, and any circumstances leading to the asplenia or splenectomy
  • Clinical diagnosis of coagulopathy (such as clotting factor deficiency, coagulation disorders, platelet abnormalities), significant bruising or blood clotting disorder
  • Acute illness or acute exacerbation of chronic disease in last 7 days
  • Any prior administration of immunodepressant or corticosteroids in last 6 months
  • Any prior administration of blood products in last 3 months
  • Any prior administration of live-attenuated vaccine in last 28 days or 1 months
  • Any prior administration of subunit or inactivated vaccines in last 14 days
  • Under the anti-TB prevention or therapy
  • Fever before vaccination, axillary temperature ﹥37.0℃
  • The laboratory test abnormalities before vaccination, including blood tests (hemoglobin, total white blood cells, WBC, platelets), blood biochemistry tests (ALT, total bilirubin, direct bilirubin, Cr, BUN) and urine tests (urine protein, urine sugar, blood cells), etc.
  • Hypertension or hypotension. Systolic blood pressure ﹥140mmHg and/or diastolic blood pressure ﹥90mmHg; systolic blood pressure ﹤90mmHg and/or diastolic blood pressure ﹤60mmHg
  • Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

For the subjects aged from 6-35 months infants:

Inclusion Criteria:

  • Healthy subjects (6-35 months infants) as established by medical history and clinical examination
  • Full-term (37-42 weeks), weight ≥ 2500 g when it was born
  • The subjects' legal guardian must be aware of this vaccines
  • The subjects' legal guardian voluntarily participate in the study and signed Informed Consent Form
  • Subjects with temperature ≤ 37.0℃
  • The subjects' legal guardian with the ability and objective to comply with the requirements of the protocol
  • Persist for a 2-month visit and receive blood tests according to program requirements

Exclusion Criteria:

  • Subject who has a clinical diagnosis history of Hand, Foot and Mouth Disease (HFMD)
  • ≤37 weeks gestation
  • weight ≤ 2500 g when it was born
  • Allergy or serious side-effects to a vaccine or any ingredient of vaccine
  • Epilepsy, seizures, convulsions, neurological illness
  • Congenital or hereditary immunodeficiency
  • Autoimmune disease
  • Severe malnutrition or dysgenopathy
  • Asthma, thyroidectomy, angioneurotic edema, diabetes or cancer
  • Asplenia, functional asplenia, and any circumstances leading to the asplenia or splenectomy
  • Clinical diagnosis of coagulopathy (such as clotting factor deficiency, coagulation disorders, platelet abnormalities), significant bruising or blood clotting disorder
  • Acute illness or acute exacerbation of chronic disease in last 7 days
  • Any prior administration of immunodepressant or corticosteroids in last 6 months
  • Any prior administration of blood products in last 3 months
  • Any prior administration of live-attenuated vaccine in last 28 days or 1 months
  • Any prior administration of subunit or inactivated vaccines in last 14 days
  • Under the anti-TB prevention or therapy
  • Fever before vaccination, axillary temperature ﹥37.0℃
  • The laboratory test abnormalities before vaccination, including blood tests (hemoglobin, total white blood cells, WBC, platelets), blood biochemistry tests (ALT, total bilirubin, direct bilirubin, Cr, BUN) and urine tests (urine protein, urine sugar, blood cells), etc.
  • Hypertension or hypotension. Systolic blood pressure ﹥140mmHg and/or diastolic blood pressure ﹥90mmHg; systolic blood pressure ﹤90mmHg and/or diastolic blood pressure ﹤60mmHg
  • Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

Sites / Locations

  • Guangxi Provincial Center for Diseases Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm 11

Arm 12

Arm 13

Arm 14

Arm 15

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

160Eu/0.5ml in adults

320Eu/0.5ml in adults

640Eu/0.5ml in adults

1280Eu/0.5ml (without adjuvant) in adults

0Eu/0.5ml in adults

160Eu/0.5ml in children

320Eu/0.5ml in children

640Eu/0.5ml in children

1280Eu/0.5ml (without adjuvant) in children

0Eu/0.5ml in children

160Eu/0.5ml in infants

320Eu/0.5ml in infants

640Eu/0.5ml in infants

1280Eu/0.5ml (without adjuvant) in infants

0Eu/0.5ml in infants

Arm Description

inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.

inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.

inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.

inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.

0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.

inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.

inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.

inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.

inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.

0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.

inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.

inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.

inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.

inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.

0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.

Outcomes

Primary Outcome Measures

Evaluate the Safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults.
Adverse reactions associated with vaccine were observed in Chinese Adults (from 18 to 49 years old) after the first vaccination.
Evaluate the Safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults.
Adverse reactions associated with vaccine were observed in Chinese Adults (from 18 to 49 years old) after the second vaccination.
Evaluate the Safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Children.
Adverse reactions associated with vaccine were observed in Chinese Children (from 3 to 11 years old) after the first vaccination.
Evaluate the Safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Children.
Adverse reactions associated with vaccine were observed in Chinese Children (from 3 to 11 years old) after the second vaccination.
Evaluate the safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants.
Adverse reactions associated with vaccine were observed in Chinese Infants (from 6 to 35 months old) after the first vaccination.
Evaluate the safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants.
Adverse reactions associated with vaccine were observed in Chinese Infants (from 6 to 35 months old) after the second vaccination.

Secondary Outcome Measures

Evaluate the seroconversion rate of anti-EV71 antibodies in serum of adults, children and infant, after first vaccination.
The seroconversion rate of anti-EV71 antibodies was evaluated in serum of adults within the first 14 days after first vaccination. The seroconversion rate of anti-EV71 antibodies was evaluated in serum of children within the first 14 days after first vaccination. The seroconversion rate of anti-EV71 antibodies was evaluated in serum of infant, within the first 28 days after first vaccination.
Evaluate the seroconversion rate of anti-EV71 antibodies in serum of adults, children and infant, after second vaccination.
The seroconversion rate of anti-EV71 antibodies was evaluated in serum of adults within the first 4 days after second vaccination. The seroconversion rate of anti-EV71 antibodies was evaluated in serum of children within the first 4 days after second vaccination. The seroconversion rate of anti-EV71 antibodies was evaluated in serum of infant, within the first 28 days after second vaccination.
Evaluate the seroconversion rate of antinuclear antibodies in serum of adults, children and infant, after first vaccination.
The seroconversion rate of antinuclear antibodies was evaluated in serum of adults within the first 14 days after first vaccination. The seroconversion rate of antinuclear antibodies was evaluated in serum of children within the first 14 days after first vaccination. The seroconversion rate of antinuclear antibodies was evaluated in serum of infant, within the first 28 days after first vaccination.
Evaluate the seroconversion rate of antinuclear antibodies in serum of adults, children and infant, after second vaccination.
The seroconversion rate of antinuclear antibodies was evaluated in serum of adults within the first 4 days after the second vaccination. The seroconversion rate of antinuclear antibodies was evaluated in serum of children within the first 4 days after the second vaccination. The seroconversion rate of antinuclear antibodies was evaluated in serum of infant, within the first 28 days after the second vaccination.
Evaluate the abnormity change of live and kidney function indexes in serum of adults, children and infant, after first vaccination.
The abnormity change of live and kidney function indexes were evaluated in serum of adults within the first 14 days after first vaccination. The abnormity change of live and kidney function indexes were evaluated in serum of children within the first 14 days after first vaccination. The abnormity change of live and kidney function indexes were evaluated in serum of infant, within the first 28 days after first vaccination.
Evaluate the abnormity change of live and kidney function indexes in serum of adults, children and infant, after second vaccination.
The abnormity change of live and kidney function indexes were evaluated in serum of adults within the first 4 days after the second vaccination. The abnormity change of live and kidney function indexes were evaluated in serum of children within the first 4 days after the second vaccination. The abnormity change of live and kidney function indexes were evaluated in serum of infant, within the first 28 days after the second vaccination.
Evaluate the vaccine-induced cellular immune responses in infant after first vaccination.
The vaccine-induced cellular immune responses were evaluated in serum of infant, within the first 28 days after the first vaccination.
Evaluate the vaccine-induced cellular immune responses in infant after second vaccination.
The vaccine-induced cellular immune responses were evaluated in serum of infant, within the first 28 days after the second vaccination.

Full Information

First Posted
July 11, 2011
Last Updated
October 7, 2023
Sponsor
Institute of Medical Biology, Chinese Academy of Medical Sciences
Collaborators
Guangxi Center for Disease Control and Prevention
search

1. Study Identification

Unique Protocol Identification Number
NCT01391494
Brief Title
A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants
Official Title
A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
February 2011 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute of Medical Biology, Chinese Academy of Medical Sciences
Collaborators
Guangxi Center for Disease Control and Prevention

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Enterovirus 71 (EV71), a major pathogen that is responsible for causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Since the late 1990s, a series of large HFMD epidemics caused by EV71 have been reported in the Asia-Pacific region. Notably, there is evidence that the most severe cases from these epidemic outbreaks are associated with neurological disorders with CNS involvement caused by EV71 infection. Because of these EV71 infection-related public health issues, the research and development of EV71 vaccine candidates have been heavily promoted. Recently, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, including inactivated vaccine, attenuated vaccine, subunit vaccine, DNA vaccine, epitope peptide vaccine, virus-like particles (VLPs). Basing on the previous studies of elicited protection in mice and rhesus monkeys, a formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been licensed by SFDA in China, Dec. 2010. The phase I clinical trial has been carried out, during four months, in Guangxi Province, China. The purpose of this study is to evaluate the safety, tolerability and immunogenicity of the formalin-inactivated EV71 vaccine in Chinese adults (from 18 to 49 years old), children (from 3 to 11 years old) and infants (from 6 to 35 months old).
Detailed Description
Hand-foot-and-mouth disease (HFMD) is a significant cause of death, usually characterized by vesicular lesions on the skin and oral mucosa and high morbidity rates in children. Additionally, occasional fatal cases have been reported involving brainstem encephalitis and myelitis associated with cardiopulmonary collapse. Pulmonary edema/hemorrhage and respiratory failure are the major causes of death among children less than five years old. Enterovirus 71 (EV71), a major pathogen that is responsible for causing HFMD worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Since the late 1990s, a series of large HFMD epidemics caused by EV71 have been reported in the Asia-Pacific region. Notably, there is evidence that the most severe cases from these epidemic outbreaks are associated with neurological disorders with CNS involvement caused by EV71 infection. Because of these EV71 infection-related public health issues, the research and development of EV71 vaccine candidates have been heavily promoted. Recently, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, including heat-inactivated or formalin-inactivated vaccine, live-attenuated vaccine, recombinant viral protein 1 (VP1) vaccine, VP1 DNA vaccine, VP1 epitope peptide vaccine, EV71 virus-like particles (VLPs) and bacterial or viral vector expressing VP1. Overall, the inactivated whole-virus vaccines seem to be more immunogenic than recombinant VP1 and DNA vaccines. Basing on the previous studies of elicited protection in mice and rhesus monkeys (Ying Zhang, et al. Pathogenesis study of Enterovirus 71 Infection in Rhesus Monkeys. Lab Invest, 2011, doi:10.1038/labinest.2011.82; Longding Liu, et al. Neonatal Rhesus Monkey is a Potential Animal Model for Studying Pathogenesis of EV71 Infection. Virology, 2011, 412:91-100; Chenghong Dong, et al. Immunoprotection Elicited by an Enterovirus Type 71 Experimental Inactivated Vaccine in Mice and Rhesus Monkeys. Vaccine, 2011, doi: 10.1016/j.vaccine.2011.06.044.), a formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been licensed by SFDA in China, Dec. 2010. The phase I clinical trial has been carried out, during four months, in Guangxi Province, China. The purpose of this study is to evaluate the safety, tolerability and immunogenicity of the formalin-inactivated EV71 vaccine in Chinese adults (from 18 to 49 years old), children (from 3 to 11 years old) and infants (from 6 to 35 months old).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hand, Foot and Mouth Disease
Keywords
Human Enterovirus 71 (EV71), Hand, Foot and Mouth Disease, Inactivated Vaccine, Human Diploid cell, Safety, Immunogenicity, Adverse reactions associated with vaccine

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
288 (Actual)

8. Arms, Groups, and Interventions

Arm Title
160Eu/0.5ml in adults
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
Arm Title
320Eu/0.5ml in adults
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
Arm Title
640Eu/0.5ml in adults
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
Arm Title
1280Eu/0.5ml (without adjuvant) in adults
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
Arm Title
0Eu/0.5ml in adults
Arm Type
Placebo Comparator
Arm Description
0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
Arm Title
160Eu/0.5ml in children
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
Arm Title
320Eu/0.5ml in children
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
Arm Title
640Eu/0.5ml in children
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
Arm Title
1280Eu/0.5ml (without adjuvant) in children
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
Arm Title
0Eu/0.5ml in children
Arm Type
Placebo Comparator
Arm Description
0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
Arm Title
160Eu/0.5ml in infants
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
Arm Title
320Eu/0.5ml in infants
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
Arm Title
640Eu/0.5ml in infants
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
Arm Title
1280Eu/0.5ml (without adjuvant) in infants
Arm Type
Experimental
Arm Description
inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
Arm Title
0Eu/0.5ml in infants
Arm Type
Placebo Comparator
Arm Description
0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
Intervention Type
Biological
Intervention Name(s)
160Eu/0.5ml in adults
Intervention Description
inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
Intervention Type
Biological
Intervention Name(s)
320Eu/0.5ml in adults
Intervention Description
inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
Intervention Type
Biological
Intervention Name(s)
640Eu/0.5ml in adults
Intervention Description
inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
Intervention Type
Biological
Intervention Name(s)
1280Eu/0.5ml (without adjuvant) in 12 adults
Intervention Description
inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
Intervention Type
Biological
Intervention Name(s)
0Eu/0.5ml in adults
Intervention Description
0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
Intervention Type
Biological
Intervention Name(s)
160Eu/0.5ml in children
Intervention Description
inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
Intervention Type
Biological
Intervention Name(s)
320Eu/0.5ml in children
Intervention Description
inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
Intervention Type
Biological
Intervention Name(s)
640Eu/0.5ml in children
Intervention Description
inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
Intervention Type
Biological
Intervention Name(s)
1280Eu/0.5ml (without adjuvant) in children
Intervention Description
inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
Intervention Type
Biological
Intervention Name(s)
0Eu/0.5ml in children
Intervention Description
0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
Intervention Type
Biological
Intervention Name(s)
160Eu/0.5ml in infants
Intervention Description
inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
Intervention Type
Biological
Intervention Name(s)
320Eu/0.5ml in infants
Intervention Description
inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
Intervention Type
Biological
Intervention Name(s)
640Eu/0.5ml in infants
Intervention Description
inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
Intervention Type
Biological
Intervention Name(s)
1280Eu/0.5ml (without adjuvant) in infants
Intervention Description
inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
Intervention Type
Biological
Intervention Name(s)
0Eu/0.5ml in infants
Intervention Description
0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
Primary Outcome Measure Information:
Title
Evaluate the Safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults.
Description
Adverse reactions associated with vaccine were observed in Chinese Adults (from 18 to 49 years old) after the first vaccination.
Time Frame
within the first 14 days after the first vaccination
Title
Evaluate the Safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults.
Description
Adverse reactions associated with vaccine were observed in Chinese Adults (from 18 to 49 years old) after the second vaccination.
Time Frame
within the first 4 days after the second vaccination
Title
Evaluate the Safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Children.
Description
Adverse reactions associated with vaccine were observed in Chinese Children (from 3 to 11 years old) after the first vaccination.
Time Frame
within the first 14 days after the first vaccination
Title
Evaluate the Safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Children.
Description
Adverse reactions associated with vaccine were observed in Chinese Children (from 3 to 11 years old) after the second vaccination.
Time Frame
within the first 4 days after the second vaccination
Title
Evaluate the safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants.
Description
Adverse reactions associated with vaccine were observed in Chinese Infants (from 6 to 35 months old) after the first vaccination.
Time Frame
within the first 28 days after the first vaccination
Title
Evaluate the safety of Inactivated EV 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants.
Description
Adverse reactions associated with vaccine were observed in Chinese Infants (from 6 to 35 months old) after the second vaccination.
Time Frame
within the first 28 days after the second vaccination
Secondary Outcome Measure Information:
Title
Evaluate the seroconversion rate of anti-EV71 antibodies in serum of adults, children and infant, after first vaccination.
Description
The seroconversion rate of anti-EV71 antibodies was evaluated in serum of adults within the first 14 days after first vaccination. The seroconversion rate of anti-EV71 antibodies was evaluated in serum of children within the first 14 days after first vaccination. The seroconversion rate of anti-EV71 antibodies was evaluated in serum of infant, within the first 28 days after first vaccination.
Time Frame
within the first 14 or 28 days after the first vaccination
Title
Evaluate the seroconversion rate of anti-EV71 antibodies in serum of adults, children and infant, after second vaccination.
Description
The seroconversion rate of anti-EV71 antibodies was evaluated in serum of adults within the first 4 days after second vaccination. The seroconversion rate of anti-EV71 antibodies was evaluated in serum of children within the first 4 days after second vaccination. The seroconversion rate of anti-EV71 antibodies was evaluated in serum of infant, within the first 28 days after second vaccination.
Time Frame
within the first 4 or 28 days after the second vaccination
Title
Evaluate the seroconversion rate of antinuclear antibodies in serum of adults, children and infant, after first vaccination.
Description
The seroconversion rate of antinuclear antibodies was evaluated in serum of adults within the first 14 days after first vaccination. The seroconversion rate of antinuclear antibodies was evaluated in serum of children within the first 14 days after first vaccination. The seroconversion rate of antinuclear antibodies was evaluated in serum of infant, within the first 28 days after first vaccination.
Time Frame
within the first 14 or 28 days after the first vaccination
Title
Evaluate the seroconversion rate of antinuclear antibodies in serum of adults, children and infant, after second vaccination.
Description
The seroconversion rate of antinuclear antibodies was evaluated in serum of adults within the first 4 days after the second vaccination. The seroconversion rate of antinuclear antibodies was evaluated in serum of children within the first 4 days after the second vaccination. The seroconversion rate of antinuclear antibodies was evaluated in serum of infant, within the first 28 days after the second vaccination.
Time Frame
within the first 4 or 28 days after the second vaccination
Title
Evaluate the abnormity change of live and kidney function indexes in serum of adults, children and infant, after first vaccination.
Description
The abnormity change of live and kidney function indexes were evaluated in serum of adults within the first 14 days after first vaccination. The abnormity change of live and kidney function indexes were evaluated in serum of children within the first 14 days after first vaccination. The abnormity change of live and kidney function indexes were evaluated in serum of infant, within the first 28 days after first vaccination.
Time Frame
within the first 14 or 28 days after the first vaccination
Title
Evaluate the abnormity change of live and kidney function indexes in serum of adults, children and infant, after second vaccination.
Description
The abnormity change of live and kidney function indexes were evaluated in serum of adults within the first 4 days after the second vaccination. The abnormity change of live and kidney function indexes were evaluated in serum of children within the first 4 days after the second vaccination. The abnormity change of live and kidney function indexes were evaluated in serum of infant, within the first 28 days after the second vaccination.
Time Frame
within the first 4 or 28 days after the second vaccination
Title
Evaluate the vaccine-induced cellular immune responses in infant after first vaccination.
Description
The vaccine-induced cellular immune responses were evaluated in serum of infant, within the first 28 days after the first vaccination.
Time Frame
within the first 28 days after the first vaccination
Title
Evaluate the vaccine-induced cellular immune responses in infant after second vaccination.
Description
The vaccine-induced cellular immune responses were evaluated in serum of infant, within the first 28 days after the second vaccination.
Time Frame
within the first 28 days after the second vaccination

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
For the subjects aged from 18-49 years old adults: Inclusion Criteria: Healthy subjects (18-49 years old adults) as established by medical history and clinical examination The subjects oneself or their legal guardian must be aware of this vaccines Voluntarily participate in the study and signed Informed Consent Form Subjects with temperature ≤ 37.0℃ With the ability and objective to comply with the requirements of the protocol Persist for a 2-month visit and receive blood tests according to program requirements Exclusion Criteria: Subject who has a clinical diagnosis history of Hand, Foot and Mouth Disease (HFMD) Allergy or serious side-effects to a vaccine or any ingredient of vaccine Epilepsy, seizures, convulsions, neurological illness Congenital or hereditary immunodeficiency Autoimmune disease Severe malnutrition or dysgenopathy Asthma, thyroidectomy, angioneurotic edema, diabetes or cancer Asplenia, functional asplenia, and any circumstances leading to the asplenia or splenectomy Clinical diagnosis of coagulopathy (such as clotting factor deficiency, coagulation disorders, platelet abnormalities), significant bruising or blood clotting disorder Acute illness or acute exacerbation of chronic disease in last 7 days Any prior administration of immunodepressant or corticosteroids in last 6 months Any prior administration of blood products in last 3 months Any prior administration of live-attenuated vaccine in last 28 days or 1 months Any prior administration of subunit or inactivated vaccines in last 14 days Under the anti-TB prevention or therapy Fever before vaccination, axillary temperature ﹥37.0℃ The laboratory test abnormalities before vaccination, including blood tests (hemoglobin, total white blood cells, WBC, platelets), blood biochemistry tests (ALT, total bilirubin, direct bilirubin, Cr, BUN) and urine tests (urine protein, urine sugar, blood cells), etc. Hypertension or hypotension. Systolic blood pressure ﹥140mmHg and/or diastolic blood pressure ﹥90mmHg; systolic blood pressure ﹤90mmHg and/or diastolic blood pressure ﹤60mmHg Breast-feeding, pregnant, planning a pregnancy within 60 days or positive pregnancy test women Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives For the subjects aged from 3-11 years old children: Inclusion Criteria: Healthy subjects (3-11 years old children) as established by medical history and clinical examination Full-term (37-42 weeks), weight ≥ 2500 g when it was born The subjects' legal guardian must be aware of this vaccines The subjects' legal guardian voluntarily participate in the study and signed Informed Consent Form Subjects with temperature ≤ 37.0℃ The subjects' legal guardian with the ability and objective to comply with the requirements of the protocol Persist for a 2-month visit and receive blood tests according to program requirements Exclusion Criteria: Subject who has a clinical diagnosis history of Hand, Foot and Mouth Disease (HFMD) ≤37 weeks gestation weight ≤ 2500 g when it was born Allergy or serious side-effects to a vaccine or any ingredient of vaccine Epilepsy, seizures, convulsions, neurological illness Congenital or hereditary immunodeficiency Autoimmune disease Severe malnutrition or dysgenopathy Asthma, thyroidectomy, angioneurotic edema, diabetes or cancer Asplenia, functional asplenia, and any circumstances leading to the asplenia or splenectomy Clinical diagnosis of coagulopathy (such as clotting factor deficiency, coagulation disorders, platelet abnormalities), significant bruising or blood clotting disorder Acute illness or acute exacerbation of chronic disease in last 7 days Any prior administration of immunodepressant or corticosteroids in last 6 months Any prior administration of blood products in last 3 months Any prior administration of live-attenuated vaccine in last 28 days or 1 months Any prior administration of subunit or inactivated vaccines in last 14 days Under the anti-TB prevention or therapy Fever before vaccination, axillary temperature ﹥37.0℃ The laboratory test abnormalities before vaccination, including blood tests (hemoglobin, total white blood cells, WBC, platelets), blood biochemistry tests (ALT, total bilirubin, direct bilirubin, Cr, BUN) and urine tests (urine protein, urine sugar, blood cells), etc. Hypertension or hypotension. Systolic blood pressure ﹥140mmHg and/or diastolic blood pressure ﹥90mmHg; systolic blood pressure ﹤90mmHg and/or diastolic blood pressure ﹤60mmHg Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives For the subjects aged from 6-35 months infants: Inclusion Criteria: Healthy subjects (6-35 months infants) as established by medical history and clinical examination Full-term (37-42 weeks), weight ≥ 2500 g when it was born The subjects' legal guardian must be aware of this vaccines The subjects' legal guardian voluntarily participate in the study and signed Informed Consent Form Subjects with temperature ≤ 37.0℃ The subjects' legal guardian with the ability and objective to comply with the requirements of the protocol Persist for a 2-month visit and receive blood tests according to program requirements Exclusion Criteria: Subject who has a clinical diagnosis history of Hand, Foot and Mouth Disease (HFMD) ≤37 weeks gestation weight ≤ 2500 g when it was born Allergy or serious side-effects to a vaccine or any ingredient of vaccine Epilepsy, seizures, convulsions, neurological illness Congenital or hereditary immunodeficiency Autoimmune disease Severe malnutrition or dysgenopathy Asthma, thyroidectomy, angioneurotic edema, diabetes or cancer Asplenia, functional asplenia, and any circumstances leading to the asplenia or splenectomy Clinical diagnosis of coagulopathy (such as clotting factor deficiency, coagulation disorders, platelet abnormalities), significant bruising or blood clotting disorder Acute illness or acute exacerbation of chronic disease in last 7 days Any prior administration of immunodepressant or corticosteroids in last 6 months Any prior administration of blood products in last 3 months Any prior administration of live-attenuated vaccine in last 28 days or 1 months Any prior administration of subunit or inactivated vaccines in last 14 days Under the anti-TB prevention or therapy Fever before vaccination, axillary temperature ﹥37.0℃ The laboratory test abnormalities before vaccination, including blood tests (hemoglobin, total white blood cells, WBC, platelets), blood biochemistry tests (ALT, total bilirubin, direct bilirubin, Cr, BUN) and urine tests (urine protein, urine sugar, blood cells), etc. Hypertension or hypotension. Systolic blood pressure ﹥140mmHg and/or diastolic blood pressure ﹥90mmHg; systolic blood pressure ﹤90mmHg and/or diastolic blood pressure ﹤60mmHg Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhaojun Mo, Master
Organizational Affiliation
Guangxi Provincial Center for Diseases Control and Prevention
Official's Role
Principal Investigator
Facility Information:
Facility Name
Guangxi Provincial Center for Diseases Control and Prevention
City
Nanning
State/Province
Guangxi
ZIP/Postal Code
530028
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
23372725
Citation
Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, Liang Z, Mao Q, Wang L, Dong C, Liao Y, Guo L, Yang E, Pu J, Yue L, Zhou Z, Li Q. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One. 2013;8(1):e54451. doi: 10.1371/journal.pone.0054451. Epub 2013 Jan 23.
Results Reference
derived
Links:
URL
http://www.nature.com/labinvest/journal/vaop/ncurrent/abs/labinvest201182a.html
Description
The rhesus monkey model may be used to study not only the basic pathogenesis of EV71 viral infections, but also to examine clinical features, such as neurological lesions, in the CNS and pathological changes in associated organs.

Learn more about this trial

A Safety Study of Inactivated EV71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Adults, Children and Infants

We'll reach out to this number within 24 hrs